@article{1ad831fb233e4994a6d8f61a4ca3e489,
title = "Results from the United States cohort of the HORIZON trial of a Schlemm canal microstent to reduce intraocular pressure in primary open-angle glaucoma",
abstract = "Purpose: To assess the safety and effectiveness of Schlemm canal stenting for reducing intraocular pressure (IOP) in combination with cataract surgery in the United States cohort of the HORIZON study. Setting: Twenty-six clinical sites in the U.S. Design: Prospective clinical trial. Methods: Eyes with mild to moderate primary open-angle glaucoma (POAG) on 1 to 4 medications, significant cataract, and an unmedicated diurnal IOP between 22 mm Hg and 34 mm Hg after medication washout were randomized 2:1 to receive the Hydrus microstent or no further treatment after successful cataract surgery. Patients were followed for 24 months. Medication washout and diurnal IOP measurements were repeated at 12 months and 24 months. Results: Two hundred nineteen eyes were randomized to microstent implantation and 112 patients to phacoemulsification only. At 24 months, the diurnal IOP was reduced by 20.0% or more in a greater proportion of eyes in the microstent group (78.5% versus 54.5%; P <.001). The mean change in the number of medications was −1.2 ± 0.9 (SD) in the microstent group and −0.8 ± 1.1 in the phaco-only group (P <.001), and 78.5% of eyes and 39.2% of eyes, respectively, were medication free (difference 38.8%; P <.001). Conclusions: Implantation of a Schlemm canal microstent after phacoemulsification significantly reduced diurnal IOP and medication use compared with phacoemulsification only in patients with mild to moderately severe POAG. The combination procedure was equivalent to cataract surgery alone in terms of visual acuity outcomes and the rate of adverse ocular events.",
author = "{HORIZON U.S. investigators} and Jason Jones and Koch, {Douglas D.} and Steven Vold and Cathleen McCabe and Douglas Rhee and Richard Lewis and Stephen Smith and Nguyen, {Quang H.} and Samuelson, {Thomas W.} and Tom Walters and Robert Marquis and Brian Flowers and Vold, {Steven D.} and Smith, {Stephen E.} and Gary Foster and Greene, {Brennan P.} and Tran, {Dan B.} and Husam Ansari and Kenneth Olander and Neil Atodaria and Mujtaba Qazi and Quang Nguyen and Edward Meier and David Godfrey and Mohammed ElMallah and Jason Levine and Johnson, {C. Stark} and Craven, {E. Randy} and Hawkins, {Richard D.} and William Clifford and Singh, {Inder Paul} and Chu, {Y. Ralph} and Crandall, {Alan C.}",
note = "Funding Information: Supported by Ivantis, Inc., Irvine, California, USA.Drs. Jones, Vold, McCabe, Rhee, Lewis, Smith, and Nguyen were investigators in the clinical trial. Drs. Lewis, Koch, and Samuelson are consultants to Ivantis, Inc. Dr. Jones reports grants and personal fees from Ivantis, Inc., during the conduct of the study and grants and personal fees from Glaukos Corp. and Alcon Laboratories, Inc./Transcend Medical, Inc., outside the submitted work. Dr. Vold reports grants from Ivantis, Inc., during the conduct of the study, personal fees from Ivantis, Inc., and grants and personal fees from Glaukos Corp., Alcon Laboratory, Inc., and Allergan, Inc, outside the submitted work. Dr. Samuelson reports personal fees from Ivantis, Inc., outside the submitted work. Dr. Rhee reports grants from Ivantis, Inc., during the conduct of the study. Dr. McCabe reports grants from Ivantis, Inc., during the conduct of the study and personal fees from Ivantis, Inc., outside the submitted work. Dr. Koch reports stock options from Ivantis, Inc., outside the submitted work. Publisher Copyright: {\textcopyright} 2019",
year = "2019",
month = sep,
doi = "10.1016/j.jcrs.2019.03.024",
language = "English (US)",
volume = "45",
pages = "1305--1315",
journal = "Journal of cataract and refractive surgery",
issn = "0886-3350",
publisher = "Elsevier Inc.",
number = "9",
}